期刊文献+

2002年至2005年临床分离的革兰氏阴性杆菌耐药监测研究及对策 被引量:1

Drug resistance study of gram - negative bacteria
下载PDF
导出
摘要 目的 探讨本地区革兰氏阴性杆菌耐药情况,为临床合理使用抗生素提供实验依据。方法 对我院近4年分离的革兰氏阴性杆菌的耐药情况及其变迁、抗生素应用情况进行回顾性分析。结果 所分离菌株耐药率较高的是氨苄西林(87.15%)、头孢拉啶(78.2%)、头孢呋辛(70.3%)、哌拉西林(62.6%)、头孢噻肟(61.2%)、复方新诺明(77.3%)。对亚胺培南、阿米卡星、哌拉西林/他唑巴坦、头孢西丁、呋喃妥因、左旋氧氟沙星、头孢他啶的耐药率依次为4.17%、13.9%、21.0%、23.7%、32.7%、36.7%、38.1%,较其他抗生素为低。铜绿假单胞菌对亚胺培南、头孢他啶、庆大霉素、阿米卡星、哌拉西林的耐药率逐年明显增高。结论 革兰氏阴性杆菌耐药日益严重,并出现多重耐药。应该在药敏结果指导下用药,适当控制抗生素应用,并注重抗生素以外的其它治疗。 Objective To study drug resistance status of Gram -negative bactria at our area and provide evidence for doctor to apply antibiotics reasonably. Methods A total of 2958 Gram -negative strains were collected from clinical specimens during the last four years. Drug resistance status and changes, and antibiotics therapy of Gram - negative bactria were analyzed retrospectively. Results In drug sensitivity result, the resistance rate of ampicillin, cephalothin, cefuroxime, piperacillin, cefotaxime and trimethoprim/sulfamethoxazole were 87.15% , 78.2% , 70.3% , 62.6% , 61.2% , 77.3% respectively. The resistance rate of imipenem, amikacin, piperacillin/tazobactam, cefoxitin, furantoin, levofloxacin, and ceftazidime were 4. 17%, 13.9% ,21.0% ,23.7% ,32.7% ,36.7% ,38.1% respectively. The resistance rate was lower than other antibiotics, ampicillin showed the highest resistance rate(87.15% ). As far as Pseudomonas aeruginosa was concerned, imipenem, cefiazidime, gentamycin, amikacin and piperacillin showed increasing resistance trend year by year. Conclusion Drug resistance of Gram - negative bactria is increasingly severely, and showes muihiple drug resistance. Antibiotics should be applied according to the result of drug sensitivity, and controlled appropriately, and pay attention to other therapy except for antibiotics.
作者 张爱荣
出处 《中原医刊》 2007年第15期15-16,共2页 Central Plains Medical Journal
关键词 革兰氏阴性杆菌 耐药性 监测 抗生素 Gram - negative bactria Drug resistance Monitor Antibiotics
  • 相关文献

参考文献9

二级参考文献59

  • 1杨青,魏泽庆,俞云松,钟步云,陈亚岗,李兰娟.重症监护病房产VIM-2型金属酶绿脓假单胞菌的研究[J].中华检验医学杂志,2004,27(10):678-682. 被引量:36
  • 2李国利,庄玉辉,那学明,曾修超,张敦镕.3种中药对分枝杆菌抗菌作用的研究[J].微生物学通报,1989,16(3):153-157. 被引量:37
  • 3Teno.,PC,徐世淞.新型感染性疾病的挑战:多药耐药病原菌的发生和传播[J].美国医学会杂志(中文版),1996,15(4):199-204. 被引量:3
  • 4Tenover FC, Mohammed MJ, Stelling J,et al. Ability of laboratories to detect emerging antimicrobial resistance: proficiency testing and quality control results from the World Health Organization's external quality assurance system for antimicrobial suscep
  • 5Chaitram JM, Jevitt LA, Lary S, et al. The world health organization's external quality assurance system proficiency testing program has improved the accuracy of antimicrobial susceptibility testing and reporting among participating laboratories using NCC
  • 6Schwaber MJ, Raney PM, Rasheed JK, et al. Utility of NCCLS guidelines for identifying extended-spectrumβ-lactamases in non-escherichia coli and non-klebsiella spp of Enterobacteriaceae. J Clin Microbil, 2004,42:294-298.
  • 7Andrews JM. For the BSAC working party on susceptibility testing. BSAC standardized disc susceptibility testing method. J Antimicrob Chemother, 2001, 48(suppl 1): 43-57.
  • 8Jorgensen JH, Turnidge JD. Susceptibility tests: dilution and disk diffusion methods. In: Murray P R, Baron EJ, Pfalier MA, et al. Mannual of Clinical microbiology,8th ed. American society for microbiology, Washington, D.C. 2003,1108-1128.
  • 9King A ,Brown DFJ.Quality assurance of antimicrobial susceptibility testing by disc diffusion. J Antimicrob Chemother, 2001, 48(suppl. S1): 71-76.
  • 10NCCLS.Perfomance standards for antimicrobial disk susceptibility tests; approved standard-eighth edition.NCCLS document M2-8[ISBN 1-56238-485-6].NCCLS,940 West valley road,suite 1400,Wayne,pennsylvania19087-1898 USA,2003.

共引文献455

同被引文献13

  • 1胡必杰,魏丽,张秀珍,唐英春,倪语星,黎毅敏,郭纪全,胡云建,张扣兴,杨莉.医院获得性肺炎发病时间对病原构成影响的回顾性队列研究[J].中华结核和呼吸杂志,2005,28(2):112-116. 被引量:48
  • 2汪光蓉,黄义山.ICU住院病人医院感染流行菌株及其耐药情况[J].世界感染杂志,2005,5(4):316-318. 被引量:12
  • 3American Thoracic Society, Infectious Diseases Society of Ameri- ca Guidelines for the management of adults with hospital - acqired, ventilator and heathcared - associated pheumonia [J]. American Jour- nal of Respiratory and Critical Care Medicine, 2005, 171 (4) : 388 -416.
  • 4National committee for clinical laboratory standards. Performance stand- ards for antimicrobial susceptibility testing; tenth inform ational supple- ment (aerobic dilution) [Z] . NCCLS, 2005: 100-514.
  • 5Soo Hoo GW, Wen YE, Nguyen TV, et al. Impact of clinical guide- lines in the management of severe hospital - acquired pneumonia [ J ]. Chest, 2005, 128:2778 -2787.
  • 6Murray CK, Hospenthal DR. Threatment of multidrug resistant Acine- obacter [J]. Curr Opin Infect Dis, 2005, 18 (6) : 502 -506.
  • 7Andriesse G1, Verhoef J. Nosocomial pneumonia; rationalizing the ap- proach to empirical therapy [ J ]. Treat Reapir Med, 2006, 5 ( 1 ) : 11 -30.
  • 8Ibrahim EH, Ward S, Sherman G, et al. A comparative analysis of pa- tients with early - onset vs late - onset nosocomial pneumonia in the ICU setting [J]. Chest, 2000, 117 (5): 1434-1442.
  • 9Rello J, Sa - Borges M, Correa H, et aL Variations in etiology of ventilator - associated pneumonia across four treatment sites: implica- tions for antimicrobial prescribing practices [ J 1. Am J Respir Crit Care Med, 1990, 160 (2): 608-613.
  • 10Leroy O, Jaffre S, D'Escrivan T, et al. Hospital - acquired pneumo- nia: Risk factors for antimierobial - resistant causative pathogens in critically ill patients [J,]. Chest, 2003, 12 (6) : 2034 -2042.

引证文献1

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部